This retrospective analysis investigated the prognostic value of del(13) and t(4;14) abnormalities and the impact of prior treatment on outcomes in 207 heavily pretreated patients with relapsed or refractory multiple myeloma (MM) treated with lenalidomide plus dexamethasone. Patients with relapsed or refractory MM who had either earlier received thalidomide or bortezomib, or for whom continuation of these agents was contraindicated, and who had fluorescence in situ hybridization data available were included in the analysis. Patients with relapsed or refractory MM who received treatment with lenalidomide plus dexamethasone in the presence of del(13) and t(4;14) chromosomal abnormalities had lower overall response rates (ORRs) and shorter median progression-free survival (PFS) and overall survival (OS) compared with those who did not have these abnormalities. The results also showed that prior treatment with bortezomib was associated with shorter median PFS and OS. Progression during thalidomide therapy was the only significant independent predictor for OS and that the presence of del(13) and hemoglobin levels o10 g per 100 ml were prognostic factors for ORR and PFS, but not OS, in these heavily pretreated relapsed or refractory MM patients treated with lenalidomide plus dexamethasone.
Introduction
Multiple myeloma (MM) is a common hematological malignancy, which accounts for B2% of all cancer deaths according to recent US statistics. 1 It is an incurable disease, but with the introduction of novel therapies, such as thalidomide, lenalidomide, and bortezomib, median survival has doubled to B4-5 years and patients now have a 20% chance of surviving longer than 10 years. 2 Lenalidomide (Revlimid; Celgene Corporation, Summit, NJ, USA) in combination with dexamethasone was shown to be highly effective in the treatment of patients with relapsed or refractory MM 3, 4 and has been approved in the European Union and the United States for the treatment of patients with MM who have received at least one prior therapy.
The chromosomal abnormalities of del (13) , t (4;14) , and del(17p) are associated with poor progression-free survival (PFS) and shorter overall survival (OS) in newly diagnosed MM patients treated with traditional chemotherapy. [5] [6] [7] [8] It was earlier reported that newly diagnosed MM patients with an abnormal karyotype treated with lenalidomide plus dexamethasone had a lower PFS and OS compared with patients with a normal karyotype. 9 Preliminary results from a study in patients with relapsed and refractory MM treated with lenalidomide plus dexamethasone showed that this combination can overcome the poor prognosis conferred by the chromosomal abnormalities of del (13) and t(4;14), but not del(17p). 10 In contrast, a recent analysis of 100 patients treated with lenalidomide plus dexamethasone at diagnosis revealed that this combination was not able to overcome the poor prognosis of chromosomal abnormalities and high labeling index. 11 The prognostic value of these cytogenetic abnormalities and the impact of prior therapy in the relapsed and refractory setting remain to be fully defined.
We performed a retrospective analysis to investigate the prognostic values of del (13) , t (4;14) , and del(17p) and the impact of prior treatment on outcomes in relapsed or refractory MM patients treated with lenalidomide plus dexamethasone.
Materials and methods
The Autorisation Temporaire d'Utilisation program, or Temporary Authorization for Use, is the regulatory mechanism used by the French Health Products and Safety Agency, which allows access of non-approved drugs to patients in France, on a named-patient basis. Medical records were obtained from 49 clinical centers participating in the French Autorisation Temporaire d'Utilisation program.
Patients with relapsed or refractory MM who had earlier received alkylating agents as well as prior thalidomide and/or bortezomib and patients with available fluorescence in situ hybridization (FISH) data were included in the analysis. Patients received oral treatment with lenalidomide (25 mg per day on days 1-21 of every 28-day cycle) plus dexamethasone (40 mg per day on days 1-4, 9-12, and 17-20 for four cycles, then days 1-4 beginning with cycle 5).
Assessments
At enrolment, FISH cytogenetic analysis was performed by two laboratories (in Nantes and Paris). CD138-purified plasma cells were analyzed for del (13) , t(4;14), and del(17p) as described earlier. 6 Response and disease progression endpoints were evaluated using the European Group for Blood and Marrow Transplantation criteria. 12, 13 OS data were collected at the time of the patients' last visit.
Statistical analyses
The independent prognostic impact of the chromosomal abnormalities del(13) and t(4;14) was analyzed by comparing the outcomes (overall response rate [ORR], PFS, and OS) of patients with or without the respective abnormality. Patient response and survival according to the presence or absence of del(17p) were not evaluable because of the small number of patients with del(17p) (n ¼ 8). The w 2 tests, Fisher's exact test, and logistic regression were used to compare ORR between groups. Time-to-event variables were estimated by KaplanMeier methods. Two-sided log-rank tests were used to compare survivorship functions between groups.
Multivariate analyses using Cox proportional-hazard regression model were performed to assess the impact of the following variables on ORR, PFS, and OS: age, sex, hemoglobin level, presence of del (13) , presence of t(4;14), prior bortezomib treatment, prior thalidomide treatment, progression on thalidomide, prior stem cell transplant, and number of lines of earlier therapy. Age, hemoglobin, and number of lines of earlier therapy were continuous variables; all other variables were dichotomous. The thresholds for entry and stay were 0.25 and 0.15, respectively. FISH data for del (13) were available in 92% (191 of 207) of patients, for t(4;14) in 89% (184 of 207) of patients, and for del(17p) in 58% (120 of 207) of patients. Del(13) was observed in 41% of analyzed patients, t(4;14) in 14% of patients, and del(17p) in 7% of patients ( 
Results

Patient characteristics
Efficacy
Among the 207 patients, the ORR was achieved in 59% of patients, including complete response in 7% and very good partial response in 14%. The median PFS was 9.6 months and the median OS was 15.1 months ( Table 2) .
Impact of chromosomal abnormalities. Among patients with del(13) compared with patients without del(13), the ORR was significantly lower, and median PFS and OS were significantly shorter, (ORR 43% vs 71%, respectively, Po0.001; median PFS 5.0 months vs 12.5 months, Po0.0001; median OS 10.4 months vs 17.4 months, P ¼ 0.001) ( Table 2; Figures 1a and b). A similar pattern was observed among patients with t(4;14) compared with patients without t(4;14) (ORR 39% vs 62%, respectively, P ¼ 0.04; median PFS 5.5 months vs 10.6 months, Po0.01; median OS 9.4 months vs 15.4 months, P ¼ 0.005) ( Table 2) .
Patients with isolated del (13), defined as the presence of del(13) without t(4;14) or del(17p), had significantly lower ORR compared with patients without isolated del(13) (43% vs 71%, respectively; P ¼ 0.01) ( Table 2 ). In contrast, the median PFS and OS were not (or marginally) shorter in patients with isolated del(13) (PFS was 8 months vs 10.4 months, P ¼ 0.05; OS was 10.8 months vs 15.1 months, P ¼ 0.56). The number of patients with del(17p) was too low for meaningful interpretation.
Impact of prior treatment. Patients who had received prior treatment with bortezomib had significantly lower ORR (55.4% vs 74.3%; P ¼ 0.04), shorter median PFS (8.3 months vs not reached; P ¼ 0.0003) and significantly shorter median OS (12.2 months vs not reached; Po0.002) compared with patients who did not receive prior bortezomib. In contrast, patients who received prior thalidomide therapy had comparable ORR (57.0% vs 69.2%; P ¼ 0.24), as well as comparable median PFS (8.5 months vs 10.6 months; P ¼ 0.10) and median OS Additional analyses were conducted to determine the combined impact of progression on thalidomide and either del (13) or prior bortezomib use on OS. For patients who did not progress on thalidomide, the median OS was 10.4 months for patients with del (13) and not reached for patients without del (13) . However, for patients who progressed on thalidomide, 
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without del(13) (median 9.5 months vs 9.7 months, respectively). For patients who progressed on thalidomide, the median OS was 11.6 months if they had prior bortezomib and not reached if they had no prior bortezomib. However, for patients with no prior bortezomib use, there was no difference in OS between patients with or without progression on thalidomide (median not reached for both).
Multivariate analyses
Multivariate analysis on ORR identified lower hemoglobin level o10 g 100 ml (hazard ratio ( (Table 4) . There was a trend toward reduced PFS with prior bortezomib use (HR: 2.37; 95% CI: 0.91-6.16; P ¼ 0.076) and increased number of prior therapies (HR: 1.17. 95% CI: 0.99-1.37; P ¼ 0.062) (Table 4) . Age, sex, prior transplant, prior thalidomide use, and t(4;14) translocation were not predictive of PFS (Table 4) .
Multivariate analysis on OS identified progression on thalidomide (HR: 1.810; 95% CI: 1.081-3.030; Po0.02) as the only significant independent predictor of reduced OS (Table 5 ). There was a trend toward reduced OS with prior bortezomib use (HR: 2.611; 95% CI: 0.927-7.360; P ¼ 0.07) ( Table 5 ). Del(13) and t(4;14) met the criteria to stay in the model though they were not statistically significant. Age, sex, number of lines of prior therapy, prior transplant, prior thalidomide treatment, and hemoglobin level did not affect OS (Table 5) .
Discussion
In this heavily pretreated population, the combination of lenalidomide plus dexamethasone achieved an ORR of 59% and median PFS of 9.6 months. These data are consistent with the results of the pivotal phase III studies in patients with more than one prior therapy (ORR 57%; median PFS 9.5 months). 3, 4 The median OS was lower in this study (15.1 months) than in the phase III studies (35.8 months). This can be explained by the higher percentage of patients with prior SCT (73% vs 53%), prior thalidomide (86% vs 52%), and prior bortezomib (81% vs 11%). In this study, multivariate analyses showed that lower hemoglobin level, increased number of prior therapies, and del (13) were independent predictors of lower ORR; that lower (13) were prognostic of reduced PFS; and that progression on thalidomide was the only significant independent predictor of OS. The chromosomal abnormalities del(13), t(4;14), and del(17p) have been associated with a decreased OS in newly diagnosed MM treated with traditional chemotherapy. 6, 7 In the presence of abnormal karyotypes, newly diagnosed MM patients treated with lenalidomide plus dexamethasone also have a shorter PFS and OS compared with patients with normal karyotypes. 9 The prognostic value of these chromosomal abnormalities has not been assessed in elderly patients with advanced heavily pretreated MM.
In this retrospective study of patients with relapsed or refractory MM who received treatment with lenalidomide plus dexamethasone, the incidence of del(13), t(4;14), and del(17p) was consistent with the incidence reported by the Intergroupe Francophone du Myélome (IFM) group. In this study of patients with relapsed or refractory MM with del(13), t(4;14), and del(17p) cytogenetic abnormalities achieved an ORR of 59%, similar to that reported (60.6%) for the overall cohort of patients in the pivotal phase III registration studies. 3, 4 Patients with del(13) and t(4;14) chromosomal abnormalities had lower ORRs and shorter median PFS and OS compared with those who did not have these abnormalities. These results partly contrast the MM-016 study by Reece et al., 10 which reported that relapsed and refractory MM patients treated with lenalidomide plus dexamethasone overcame poor prognosis conferred by the chromosomal abnormalities of del(13), t(4;14), but not del(17p), as evidenced by the findings that the advantage in TTP and OS conferred by the addition of lenalidomide to dexamethasone were independent of del(13) or t(4;14) abnormalities. However, the study also reported that both del(13q) and t(4;14) were associated with shorter TTP in univariate analyses, and that the ORRs in patients with del(13q), t(4;14), and del(17p13) (76.4, 78.6 and 58.3%, respectively) were lower than reported for the overall study population (83.1%). The partial contrast between these findings could be a result of differences in patient characteristics between the two studies. Patients in our study were older (median age of 65 years vs 61 years), had a higher median number of prior therapies (3 vs 2), and a higher proportion of patients with earlier thalidomide (86% vs 54%) or bortezomib (81% vs 46%) therapy. However, our results confirm those observed in newly diagnosed patients, although the definition of high-risk patients was slightly different. 11 Another finding in this study is the prognostic value of isolated del (13) . In studies analyzing patients at diagnosis, isolated del(13) (that is not associated with t(4;14) or del(17p)) was not associated with a particular outcome. In other words, all the prognostic value of del (13) was related to the prognostic impact of related chromosomal abnormalities. In this study, del(13) was associated with a lower ORR and a shorter PFS. This may suggest that del(13) displays a different prognostic value at diagnosis and in later phases of the disease.
Most patients in this study had received earlier thalidomide (81%) and/or bortezomib (86%) therapy. Wang et al.
14 reported that efficacy of lenalidomide and dexamethasone was superior to dexamethasone alone in patients with relapsed or refractory MM treated with lenalidomide and dexamethasone regardless of prior thalidomide exposure. The efficacy results were more favorable for patients without than with prior thalidomide treatment; however, this was also observed for patients treated with dexamethasone alone and probably reflects the fact that patients with prior thalidomide exposure were more heavily pretreated (median 3 vs 2 prior therapies). In this study, we found that prior thalidomide made no difference in PFS or OS according to univariate and multivariate analyses, but that patients who progressed on thalidomide had shorter OS than patients who had not progressed on thalidomide. In addition, for patients who had not progressed on thalidomide, those without del(13) had better OS than patients with del(13); however, for patients who had progressed on thalidomide, the presence of del (13) did not have an adverse effect on OS. Patients who were resistant to thalidomide had an additional line of prior therapy (median of 4 vs 3 prior lines) and a higher incidence of t(4;14) (16% vs 9%) than patients who were not resistant to thalidomide, which may account for poorer outcomes observed in these patients. However, the main explanation is probably a cross-resistance between the two related drugs. Finally, patients who had received prior bortezomib therapy had significantly shorter median PFS and OS compared with those with no earlier bortezomib treatment. Our data show that OS is only compromised in patients who progressed on thalidomide if they received prior bortezomib, which suggests that bortezomib may induce resistance to late salvage therapy. This could be related to the adaptive mechanisms, which allow cells to develop resistance to proteasome inhibitors and establish a hyperproliferative and apoptosis-resistant phenotype. 15, 16 However, we have to stress that patients who did not receive bortezomib presented a lower median number of lines of treatment (median ¼ 2), than those who receive prior bortezomib (median ¼ 4).
In relapsed or refractory MM patients with del(13), outcomes reported here for lenalidomide and dexamethasone are comparable with those reported for bortezomib in a consecutive patient Lenalidomide and cytogenetics in myeloma H Avet-Loiseau et al cohort (ORR 45%; OS 9.9 months) 17 and in a retrospective analysis of the SUMMIT (ORR 24%; OS 10.0 months) and APEX (ORR 20-53%; OS 10.0 months to not reached) trials. 18 In the consecutive patient cohort, the authors reported no significant difference in outcomes between patients with and without del(13); however, median time from initiation of first-line therapy was significantly shorter in patients with than without del(13) (26 months vs 51 months; P ¼ 0.02). 17 In the retrospective analysis, prognosis appeared to be poorer in patients with del (13) in both studies, but the differences were not statistically significant in the matched-pairs analyses (selected groups of patients balanced for age and ISS parameters). 18 Our study adds new data with regard to the prognostic value of high-risk cytogenetic abnormalities in relapsed or refractory MM treated with novel therapies. The data are limited by the retrospective nature of the analysis and the relatively high rate of missing data. These results are not completely consistent with currently available data and further clarification is required, ideally by prospective studies.
In conclusion, multivariate analyses showed that an increased number of prior therapies was predictive of lower ORR; lower hemoglobin level and the presence of del (13) were prognostic of reduced ORR and lower median PFS; and progression on thalidomide was an independent predictor of both PFS and OS. This study confirms the beneficial effects of lenalidomide and dexamethasone in this heavily pretreated population and suggests that because of a better toxicity profile, lenalidomide should be proposed earlier in the patient evolution. Randomized clinical trials are needed to further evaluate these findings.
